Hikma names ex-Fresenius scientist as global R&D chief

Hikma products (Hikma)

Hikma Pharmaceuticals has named Surendera Tyagi, Ph.D., as its CSO and global head of R&D. Tyagi joins Hikma with a brief to stimulate noninjectable R&D activity at a time when its generic drug unit is suffering.

The CSO is joining Hikma from Fresenius Kabi. Tyagi joined Fresenius Kabi in 2008 and went on to expand its cancer business and take charge of a U.S. innovation and development center. Earlier in his career Tyagi held positions at companies including Dabur Pharma, Roche, IGEN, Abbott and Schwarz Pharma.

Hikma hopes to tap into the experience Tyagi accrued in these roles to expand its pipeline and accelerate the progress of its top prospects. For the first year, Tyagi will focus on the noninjectable side of Hikma’s business. 

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Tyagi’s appointment follows a 12-month period in which Hikma’s stock fell by more than 40%. Investors drove down the price of the stock throughout the last nine months of 2017 as news of the difficulties of bringing a generic version of GlaxoSmithKline’s Advair to market in the U.S. and the woes of the broader off-patent unit dripped out.

Hikma sees research and innovation as one of the ways to dig itself out of its current predicament. And it views Tyagi as the right person to execute this part of its growth strategy. 

"Surendera is an outstanding scientist with a proven track record of leading research and development in some of the world's largest and most successful pharmaceutical organizations," Hikma CEO Saïd Darwazah said in a statement. “Research and Innovation is one of our five pillars for growth and the appointment of Surendera is a significant step forward in executing on this strategy.”

Suggested Articles

Janssen is planning its first completely virtual clinical trial, using personal smartphones and wearable devices with no in-person site visits.

Sensyne Health aims to bring its AI tools to America, and it’s enlisting IT giant Cognizant and data infrastructure specialist Agorai to help.

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.